BUCELLI, CRISTINA
BUCELLI, CRISTINA
Universita' degli Studi di MILANO
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis
2024 D. Capitanio, F.R. Calledda, V. Abbonante, D. Cattaneo, M. Moriggi, B. Niccolò, C. Bucelli, D. Tosi, U. Gianelli, A.M. Vannucchi, A. Iurlo, C. Gelfi, A. Balduini, A. Malara
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
2023 T. Barbui, A.M. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, G. Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi
Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study
2022 S. Fabris, D. Cattaneo, S. Salerio, C. Bucelli, G. Ciceri, R. Pasquale, K. Todoerti, U. Gianelli, L. Baldini, A. Neri, A. Iurlo
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
2021 T. Barbui, A.M. Vannucchi, V. De Stefano, A. Masciulli, A. Carobbio, A. Ferrari, A. Ghirardi, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G.G. Loscocco, P. Guglielmelli, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy)
2020 B. Fattizzo, J.A. Giannotta, W. Barcellini, M.C. Barbanti, C. Bucelli, R. Cassin, D. Cattaneo, F. Cavallaro, V. Ferla, N.S. Fracchiolla, A. Freyrie, G. Galassi, M.C. Goldaniga, F.I. Grifoni, A. Iurlo, G. Mangiameli, V. Mattiello, M. Meli, A. Neri, A. Noto, F. Onida, L. Ottani, R. Pasquale, L. Pettine, A. Pompa, G. Reda, F.G. Rossi, G.N. Saporiti, M. Sciumè, E. Tagliaferri, L. Baldini
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
2020 B. Rocca, A. Tosetto, S. Betti, D. Soldati, G. Petrucci, E. Rossi, A. Timillero, V. Cavalca, B. Porro, A. Iurlo, D. Cattaneo, C. Bucelli, A. Dragani, M. Di Ianni, P. Ranalli, F. Palandri, N. Vianelli, E. Beggiato, G. Lanzarone, M. Ruggeri, G. Carli, E.M. Elli, M. Carpenedo, M.L. Randi, I. Bertozzi, C. Paoli, G. Specchia, A. Ricco, A.M. Vannucchi, F. Rodeghiero, C. Patrono, V. de Stefano, T. Za, A. Ciminello, F. Bartolomei, G. de Santis, I. Nichele, S. Bellesso, S. Artuso, G. Summa, C. Santone, G. Auteri, S. Giaquinta, M. Arminio, S. Priolo, G. Bogoni, P. Guglielmelli, F. Mannelli, G. Coltro, E. Ravenda, F. Albano, P. Carluccio, M. Gentile, E. Carafelli
Management of Myelofibrosis : from Diagnosis to New Target Therapies
2020 A. Iurlo, D. Cattaneo, C. Bucelli
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series
2020 A. Iurlo, F. Palandri, E. Maria Elli, D. Cattaneo, C. Bucelli, M. Sciume, D. Vincelli, F. Brioschi, G. Auteri, G.A. Croci, S. Guerneri, G. Isimbaldi, E. Sabattini, I. Cortinovis, A. Bossi, V. Rosti, B. Martino, L. Baldini, U. Gianelli
New perspectives on polycythemia vera : from diagnosis to therapy
2020 A. Iurlo, D. Cattaneo, C. Bucelli, L. Baldini
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality
2020 B. Fattizzo, J.A. Giannotta, M. Sciume, D. Cattaneo, C. Bucelli, N.S. Fracchiolla, F. Onida, L. Baldini, W. Barcellini, A. Iurlo
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis : a practical approach
2019 A. Iurlo, E.M. Elli, F. Palandri, D. Cattaneo, A. Bossi, I. Cortinovis, C. Bucelli, N. Orofino, F. Brioschi, G. Auteri, P. Bianchi, S. Fabris, G. Isimbaldi, E. Sabattini, L. Baldini, U. Gianelli
UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia
2019 A. Iurlo, C. Bucelli, D. Cattaneo, G.V. Levati, B. Viani, D. Tavazzi, D. Consonni, L. Baldini, M.D. Cappellini
Osteolytic lesions in primary myelofibrosis and effect of ruxolitinib therapy : Report of a case and literature review
2018 C. Bucelli, D. Cattaneo, V.B. Valli, G.V. Levati, S. Lonati, U. Gianelli, A. Iurlo
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
2018 A. Iurlo, S. Galimberti, E. Abruzzese, M. Annunziata, M. Bonifacio, R. Latagliata, P. Pregno, D. Ferrero, F. Sorà, E.M. Orlandi, C. Fava, D. Cattaneo, C. Bucelli, G. Binotto, E. Pungolino, M. Tiribelli, A. Gozzini, G. Gugliotta, F. Castagnetti, F. Stagno, G. Rege-Cambrin, B. Martino, L. Luciano, M. Breccia, S. Sica, M. Bocchia, F. Pane, G. Saglio, G. Rosti, G. Specchia, A. Cortelezzi, M. Baccaran
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients : A Safe and Effective Option
2018 A. Iurlo, D. Cattaneo, N. Orofino, C. Bucelli, M. Molica, M. Breccia
Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
2017 U. Gianelli, S. Fiori, D. Cattaneo, A. Bossi, I. Cortinovis, A. Bonometti, G. Ercoli, C. Bucelli, N. Orofino, G.P. Bulfamante, A. Iurlo
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
2017 S. Galimberti, C. Bucelli, E. Arrigoni, C. Baratè, S. Grassi, F. Ricci, F. Guerrini, E. Ciabatti, C. Fava, A. D'Avolio, G. Fontanelli, G. Rege Cambrin, A. Isidori, F. Loscocco, G. Caocci, M. Greco, M. Bocchia, L. Aprile, A. Gozzini, B. Scappini, D. Cattaneo, A.R. Scortechini, G. La Nasa, A. Bosi, P. Leoni, R. Danesi, G. Saglio, G. Visani, A. Cortelezzi, M. Petrini, A. Iurlo, A. Di Paolo
An unusual type of myeloid sarcoma localization following myelofibrosis : a case report and literature review
2017 N. Orofino, D. Cattaneo, C. Bucelli, L. Pettine, S. Fabris, U. Gianelli, N.S. Fracchiolla, A. Cortelezzi, A. Iurlo
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy : Report of a Case
2017 C. Bucelli, D. Cattaneo, V. Ferla, M. Zappa, C. de Benedittis, S. Soverini, A. Iurlo
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia
2017 A. Iurlo, C. Bucelli, D. Cattaneo, N. Orofino, J.A. Giannotta, M. Zappa, U. Gianelli, A. Cortelezzi